Peptides with diverse amino acid sequences, structures, and functions are essential players in biological systems. The construction of well-annotated databases not only facilitates effective information management, search, and mining but also lays the foundation for developing and testing new peptide algorithms and machines. The antimicrobial peptide database (APD) is an original construction in terms of both database design and peptide entries. The host defense antimicrobial peptides (AMPs) registered in the APD cover the fi ve kingdoms (bacteria, protists, fungi, plants, and animals) or three domains of life (bacteria, archaea, and eukaryota). This comprehensive database ( http://aps.unmc.edu/AP ) provides useful information on peptide discovery timeline, nomenclature, classifi cation, glossary, calculation tools, and statistics. The APD enables effective search, prediction, and design of peptides with antibacterial, antiviral, antifungal, antiparasitic, insecticidal, spermicidal, anticancer activities, chemotactic, immune modulation, or antioxidative properties. A universal classifi cation scheme is proposed herein to unify innate immunity peptides from a variety of biological sources. As an improvement, the upgraded APD makes predictions based on the database-defi ned parameter space and provides a list of the sequences most similar to natural AMPs. In addition, the powerful pipeline design of the database search engine laid a solid basis for designing novel antimicrobials to combat resistant superbugs, viruses, fungi, or parasites. This comprehensive AMP database is a useful tool for both research and education.
Introduction
There are at least two good reasons for our current focus on host defense antimicrobial peptides (AMPs). First, AMPs have remained potent for millions of years. Therefore, AMPs constitute useful templates for developing a new generation of antimicrobials to meet the growing antibiotic resistance problem worldwide. Second, AMPs are key components of the innate immune system universally required for the survival of both invertebrates and vertebrates. Thus, research in this direction improves our understanding of innate immunity and its relationships with the adaptive immune system in vertebrates [ 1 -6 ] .
Lysozyme, discovered by Alexander Fleming in 1922, is now recognized as the fi rst antimicrobial peptide. However, there was little research on AMPs until the discoveries of cecropins, defensins, and magainins in the 1980s [ 7 -9 ] . Since then, AMPs have been identifi ed from a variety of living species. Select AMPs identifi ed during 1922-2012 are listed in the discovery timeline page of the antimicrobial peptide database (APD) [ 10 , 11 ] . In earlier days when the number of AMPs was limited, these peptides were handled in review articles. With a rapid increase in the number of such peptides, it became impractical to continue to manage them manually. As a consequence, several databases have been established to categorize these peptides [ 10 -31 ] . AMSDb appears to be the fi rst such database available online in 1998 [ 12 ] . The information format of this database is identical to the SWISS-Prot (UniProt) [ 32 ] . It contains 895 antimicrobial peptides, proteins, and their precursors from plants and animals. Unfortunately, AMSDb is no longer updated. To meet the need of better databases with a broad scope, two general databases were published side by side in 2004. ANTIMIC reported more than 1,700 entries [ 13 ] , while a new version of ANTIMIC called DAMPD [ 14 ] contains 1,232 entries. In 2004, the fi rst version of the APD [ 10 ] reported 525 peptide entries. These peptides were manually collected from the literature with the aid of public search engines such as PubMed, Swiss-Prot, and PDB [ 32 -34 ] . The peptide number reached 1,228 entries in the second version of the APD [ 11 ] and there are 2,329 peptide entries in the current version.
Since the publication of APD and ANTIMIC, several specialized databases have been established to emphasize certain aspects of natural, synthetic, or recombinant AMPs from a special peptide family (circular peptides, defensins, and thiopeptides) or source (e.g., bacteria, plants, shrimps, amphibians) [ 15 -28 ] . For example, defensin knowledgebase is dedicated to defensins only, while DADP contains only polypeptides from frogs. More recently, the CAMP [ 29 ] , YADAMP [ 30 ] , and LAMP [ 31 ] have also been built. Table 1 lists major databases dedicated to AMPs. Among these databases, the APD [ 10 , 11 ] stands out. This article highlights the unique aspects of the APD as well as new developments since the publication of the second version in 2009.
Database Design and Search Functions
In terms of peptide registration, the APD database [ 11 ] follows a set of self-defi ned criteria. First, the peptide must have a known amino acid sequence, at least partially. Second, the peptide should have demonstrated antimicrobial activity. Third, the peptide Adapted from the APD website ( http://aps.unmc.edu/AP/links.php ) [ 10 , 11 ] The Antimicrobial Peptide Database contains less than 100 amino acids (this has recently been expanded to 200 amino acids so that some important antimicrobial proteins could be collected). Fourth, the peptide originates primarily from natural sources, including bacteria, protozoa, fungi, plants, and animals. Only a small set of synthetic peptides of general interest was collected. Also, the APD emphasizes unique sequences. Therefore, peptides from different species currently occupy the same entry in this database if they share the same amino acid sequence. At present, there are 46 such entries in the APD, which were "found in multiple species" (the quoted phrase can be searched in the additional information fi eld). Since in silicopredicted peptides may not be truly antimicrobial peptides, they are not registered into the APD at this stage. By following the above criteria, the APD database provides a well-defi ned set of peptides to the research community. Indeed, the APD is a wellrecognized resource in the fi eld of AMPs. For example, the web hits were ~15,000 per year prior to 2008 [ 11 ] . Since the publication of the second version in 2009, there is a dramatic increase in database use. For example, the web hits reached 86,000 in 2012 alone.
Criteria for Peptide Collections
The design of any database is to facilitate information search. Users can conduct a simple search by using peptide name and amino acid sequence in single-letter code. Different from other databases in Table 1 , the power of the APD search engine can be ascribed to two important features. First, the search engine is composed of a pipeline of search functions. Second, the modular design of the APD enables continued expansion and development. These features greatly facilitate information search at an advanced level. For example, we obtained 268 defensins using the word "defensin" as a search term. The number of defensins rapidly reduced to 19 when the word "monkey" is also used. Only seven peptides were found when a combination of "defensin," "monkey," and "theta" are used.
To make it easier for the APD users, Table 2 lists major search functions, peptide information, and examples. Most of these search functions are self-explanatory. The name fi eld of the APD, however, has been substantially expanded and deserves some description. It consists of the following elements:
Peptide name + family name + peptide source kingdom + posttranslational modifi cation + peptide binding molecules .
In the beginning, it gives peptide name, including synonyms and even the outdated names. In the case of human cathelicidin LL-37, the word LL37 is also used in the literature and FALL-39 is an outdated name. To help users to understand the AMP nomenclature, the major methods used to name AMPs are These include the peptide property-based method, the source-based method, and a third method that uses both peptide features and source information. For examples, please visit the APD website. After the peptide name, the peptide family name is also given in the NAME fi eld. Selected AMP families are tabulated in Table 3 . Using the peptide family name, one can obtain a list of AMPs from the same family. For example, there are 268 defensins from a variety of sources and 185 brevinins from amphibians.
A Flexible Database Design

Database Search Functions
Following the family name, the peptide is further annotated in the NAME fi eld based on the source domains or kingdoms. The fi ve kingdoms of life are bacteria, protists (protozoa + algae), fungi, plants, and animals [ 35 ] , while the three domains of life are bacteria, archaea, and eukaryotes [ 36 ] . The peptide counts in each kingdom are listed in Table 4 . Selected classes in each life domain are also given in the NAME fi eld, allowing users to focus only on the AMPs of their interest.
The importance of post-translational modifi cations (PTMs) is only secondary to the peptide sequence itself [ 37 ] . Because PTMs could infl uence both structure and function of the peptide, it is necessary to annotate sequence modifi cation information in the same location. Table 5 contains 23 types of PTMs in the APD. To our knowledge, the APD is the only AMP database that contains extensive information on peptide chemical modifi cations. In addition, the effect of chemical modifi cation on a peptide net charge is considered in the APD. How AMPs kill pathogens is an important question to ask. The information for binding targets of AMPs is also annotated in the APD (Table 6 ). In addition to membranes, AMPs can bind to DNA, heat shock proteins, carbohydrates, and lipid II [ 1 -6 ] .
Classifi cation of AMPs Based on Peptide Activity, 3D Structure, and Chain Bonding Pattern
There are a variety of approaches for classifying AMPs. Some of these methods are summarized on the classifi cation page of the APD website (aps.unmc.edu/AP/class.php). For example, the peptides may be classifi ed based on the biosynthesis machinery. Some peptides are synthesized by a multiple enzyme system, while the majority of AMPs are gene-coded. The expression and degradation of gene-coded AMPs are elegantly regulated because either over or under expression of AMPs could cause problems [ 1 -5 ] . AMPs can also be classifi ed based on molecular targets (e.g., membrane targeting and cell-penetrating peptides) [ 6 ] . In the following, we fi rst describe structure and activity-based classifi cation schemes in the APD and then introduce a universal classifi cation scheme for antimicrobial peptides.
As key effector molecules of innate immunity, AMPs are able to control invading pathogenic microbes, including bacteria, viruses, fungi, and parasites [ 1 -4 ] . It is natural to classify these host defense peptides based on their functions, including antibacterial, antiviral, antifungal, insecticidal, and spermicidal activities. In addition, some AMPs also possess other functional roles such as anticancer, wound healing, and immune modulation [ 4 ] . The APD database has annotated 17 types of peptide activities or functions (Table 7 ) . Several newly annotated activity types are unique in this database, making the APD most comprehensive in terms of activity annotation. This number was obtained by searching for disulfi de bond-containing AMPs classifi ed as "Bridge," "β structure," and "αβ structure" families, respectively. The "bridged" AMPs are known to have disulfi de bonds but unknown 3D structure. Beta structures without disulfi de bonds were excluded by including "c" as a sequence search term. For the αβ structures, only the AMPs with a packed 3D fold were counted According to the APD, only a small population of AMPs (13 %) has a known 3D structure, primarily determined by solution nuclear magnetic resonance (NMR) spectroscopy [ 10 ] . In addition, X-ray diffraction was also used to solve the structures of some AMPs with a folded structure in water. The structural information is well annotated in the APD database, including structural class, method for structural determination, structural regions, key residues, and membrane-mimetic models for structural determination. In addition, users can directly view the 3D structure via the link to the PDB [ 33 ] . The AMP structures are usually classifi ed into α-helical, β-sheet, and extended structures [ 4 , 38 ] . A more general classifi cation approach has been proposed recently [ 6 ] . In this approach, the AMP structures are classifi ed into four families: α, β, αβ, and non-αβ based on the types of secondary structures. Peptides in the α family contain α-helical structure (Fig. 1a ) as the major secondary structure. In contrast, AMPs in the β family are characterized by at least a pair of two β-strands in the structure (Fig. 1b ) . The αβ family contains both α and β structures (Fig. 1c ) , whereas the non-αβ family has neither α nor β structure (Fig. 1d ). This structural classifi cation scheme is now executed in the APD. Typical examples and peptide counts from different families are provided in Table 8 . While the α-helical family is the largest with 328 entries, the non-αβ family is the smallest with merely 9 entries. families differ. While lysines are dominant in the α-helical family, arginines are preferred in the β-family as well as the non-αβ family. Not surprisingly, AMPs with both α and β structures have a moderate K / R ratio of ~1.2. These ratios might become useful as indicators for classifying a newly discovered peptide into a particular structural family.
Antimicrobial Activity
Because only a small number of AMPs has a 3D structure, we herein propose a systematic classifi cation approach that is independent of 3D structure, peptide source, or activity. This classifi cation is framed based on the connection mode of polypeptide chains. Class I includes linear AMPs (Fig. 2a ) , which may be chemically modifi ed (amidation, sulfate, phosphate, bromide, or glycosylation) at side chains or even backbones. However, such modifi cations (Table 5 ) for class I AMPs do not lead to chain connections between different amino acids. Class II covers all AMPs with chemical bonds between different peptide side chains (Fig. 2b ) . These include lantibiotics (thioether rings) and the defensin family (disulfi de bonds). Broadly, it can be any type of chemical connections between two amino acids. When two or more peptides work together, they belong to this class as long as any of the polypeptide chain contains a sidechain-sidechain connection. Class III AMPs must possess a chemical bond between peptide side chain and backbone (Fig. 2c ) . The typical members are lassos where the carboxyl group of residue E8 or D9 is covalently linked to the N-terminal amine group. It can be any type of chemical bonding between the side chain of one amino acid and the backbone of another amino acid ( see Table 9 ). Lastly, class IV is composed of circular peptides where a peptide bond is formed between the amino and carboxylic ends of the peptide backbone (Fig. 2d ) . These circular peptides may (or may not) contain additional modifi cations such as disulfi de bonds. Examples are enterocin AS-48 from bacteria, cyclotides from plants, and θ-defensins from primates [ 37 ] . Each class of AMPs can be further classifi ed. For class I peptides, they can be classifi ed into two subclasses based on the number of polypeptide chains (Table 9 ). Single-chain linear AMPs are further classifi ed based on chemical modifi cations. Unmodifi ed AMPs include "amino acid rich" and "not amino acid rich" families. Modifi ed peptides are further divided into two types based on modifi cation sites (side chain or backbone). These systematic classifi cations for class 1 AMPs are summarized in Table 10 with examples. Likewise, class II AMPs with connections between side chains can be further classifi ed based on the number of polypeptide chains as well as the type of chemical bonds (Table 9 ) . A further classifi cation of the single-chain disulfi de-bonded AMPs (e.g., defensins or defensin-like) based on the number of S-S bonds is provided in Table 11 . It is also possible to further classify single-chain lantibiotics based on the number of thioether bonds (Table 12 ) . A new type of sidechain-sidechain connection will constitute a new subclass. In the same vein, class III AMPs can be further separated into different types based on the bond type (Table 9 ). This chemical bond-based classifi cation is also extended to class IV. Circular AMPs are classifi ed based on the additional types and number of chemical bonds in the polypeptide chain (Table 13 ). This systematic classifi cation system covers all AMPs and should complement with the existing classifi cation systems proposed for AMPs from different life domains [ 39 -43 ] . Post-translational modifi cation (PTM) is a broad concept that includes all types of functional groups attached to the peptide chain via covalent bond formation. A detailed list of PTMs is provided in Table 5 . Some common examples are N-terminal acetylation, C-terminal amidation, phosphorylation, glycosylation, aromatic halogenation, and sulfation. In the extreme case, even the peptide backbone is modifi ed, leading to dehydrated or heterocycles. However, all these modifi cations are limited to a single amino acid and do not lead to a polypeptide chain connection between different amino acids as observed in the other three major classes of AMPs (Table 9 ) b AA = Amino acids The peptides can further be classifi ed into subtypes based on 3D structure (A: α-helical; B: β-sheet-containing (β and αβ families); C: non-αβ; D: unclassifi ed due to an unknown 3D structure) Table 13 Classifi cation of circular antimicrobial peptides (UCBB1a)
A Universal Classifi cation of AMPs Based on Peptide Bonding Patterns
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Additional links Examples
A None Bacterial enterocin AS-48
Peptide Prediction
Based on the information content used in the prediction programs, the prediction methods of AMPs have been classifi ed into fi ve types [ 6 ] . The fi rst type uses only mature peptide sequences, while the second method involves only the precursor sequences. The third prediction type considers both mature and precursor sequences. The fourth method employs the sequence similarity of the modifying enzymes. Finally, the fi fth prediction uses genomic information. It is possible that each prediction above can be achieved in different ways. For example, based on the mature AMP sequences in the APD [ 10 , 11 ] , numerous prediction methods have been developed. In the Lata method [ 44 ] , two data sets were utilized: antimicrobial and non-antimicrobial. While it is easy to download the positive data set from the APD, it is diffi cult to get a true negative data set because the activities of the sequences in the negative data set have not been validated by experiments. Yet the program is set up with a good predictive ability. A recent prediction method iAMP-2L [ 45 ] considers multiple functions of AMPs annotated in the APD. Different from all other prediction protocols (reviewed in ref. 6 ), a unique prediction method is programmed in the APD. This method does not require a negative data set, but is coupled with the database. In the following, we describe an upgraded version of this APD method. The original prediction method in the APD made predictions based on some known rules [ 10 ] . Hence, the method was referred to as knowledge-based prediction. For example, AMPs are usually cationic. A peptide with a negative net charge was predicted as "less likely to be an antibacterial peptide." This simple prediction has its limitations because the database does contain anionic AMPs. To overcome this shortcoming, we have updated the prediction interface based on the parameter space defi ned by the whole peptide set in the APD. The parameters for antimicrobial peptides are better defi ned due to a fourfold increase in peptide number from the original 525 to the current 2,329. Peptide parameters such as length, net charge, hydrophobic percentage, and amino acid composition can all be calculated. These parameters constitute the parameter space of natural AMPs .
In terms of net charge, the known AMPs occupy a very broad range. The AMP with the most negative net charge is chrombacin (net charge −12). Two AMPs, sheep cathelicidin OaBac11 and fi sh histone-derived Oncorhyncin II, possess the highest net charge of +30. Thus, the boundary conditions for net charge are defi ned as −12 < net charge < +30.
The above boundary condition can be incorporated into the APD program to make database-based predictions. This expansion enables the prediction of a broader range of peptide sequences. Because the majority of the AMPs (97.4 %) have a net charge between −5 and +10, it may be useful to defi ne this range as the core region. The small number of AMPs outside the core region may be called the minor region. This core region may be used as an alternative condition for prediction.
The hydrophobic content (i.e., the sum of hydrophobic amino acids divided by the total number of amino acids in a peptide) is another important parameter that determines peptide properties. In the APD, hydrophobic amino acids include alanines (Ala), valines (Val), leucines (Leu), isoleucines (Ile), methionines (Met), phenylalanines (Phe), tryptophans (Trp), and cysteines (Cys) [ 10 ] . Based on the database sorting function, we identifi ed the AMPs with the lowest and highest hydrophobic contents. Sheep anionic peptide SAAP (sequence: DDDDDD) contains no hydrophobic residues in the sequence, leading to a hydrophobic content of 0 %, while gramicidins have the highest hydrophobic content of 93 %. Thus, the boundary conditions for peptide hydrophobic contents are defi ned as 0 % ≤ hydrophobic content < 93 %.
The peak of this hydrophobic distribution is located between 40 and 50 % [ 46 ] . This leads to another set of boundary conditions for our database-based prediction. We can also defi ne the core region based on the hydrophobic content. The AMPs in the core region (98.6 %) possess a hydrophobic content between 10 and 80 %.
The length of the peptides in the current APD ranges from 5 to 174. The lower limit is real, while the upper limit is arbitrary since it is defi ned by the scope of peptides collected into the database (<200 amino acids). However, the majority of AMPs (92.9 %) are less than 60 amino acids in length, leading to a defi nition of the core length region of 5-60. We can anticipate that these boundary conditions will be fully determined when a suffi cient number of representative natural AMPs have been identifi ed and registered into the APD.
During this study, we have executed these new databasederived boundary conditions in the prediction interface of the APD (Fig. 3 ) . This interface makes predictions based on sequence similarity. In the fi rst step, the prediction program will calculate the peptide parameters based on the input sequence. The calculated peptide parameters will then be compared with the APD parameter space. If one or more calculated parameters fall outside the database-defi ned parameter space, the users will be informed that "your input is less likely to be an antibacterial peptide." If all the parameters fall within the defi ned parameter space, the database will conduct a second tier of prediction by broadly classifying input peptides into several classes: rich in amino acids (>25 % for any amino acid), helical, and disulfi de-linked. With the execution of the universal classifi cation proposed in Table 9 , a more accurate prediction will be realized. As the third tier of our prediction, the database compares the input sequence with all the peptides in the database by performing sequence alignment. Five peptides with Fig. 3 Prediction of antimicrobial peptides based on the antimicrobial peptide database. The prediction consists of three steps. As the fi rst step, the program will determine whether the input sequence is in the database-defi ned parameter space (such as charge and hydrophobic content). If identical, the users will be informed. If one or more calculated parameters of the input peptide are out of the boundaries, it is predicted as "your sequence is less likely to be an antibacterial peptide." Second, the input sequence will be classifi ed into three families: rich in amino acids such as histatins and tryptophans, disulfi de-linked peptides, and linear. Third, sequence alignments will be conducted to fi nd fi ve peptides that are most similar to the query sequence most similar sequences will be provided in the output. Because we use database-derived parameters for prediction, we refer to this upgraded method as the APD-based prediction (the November 2013 version). Compared to the original prediction [ 10 ] , the upgraded version is able to handle a broader range of peptide sequences. In addition, the chance of identifying the most similar sequences in the APD also increases substantially as a consequence of a fourfold increase in natural compounds.
The identifi cation of most similar AMPs is a useful feature. For example, O'Shea did not fi nd similar sequences by searching the BLAST database [ 47 ] , but were able to do so using the APD. Based on the sequence similarity of a novel bacteriocin with plant Ib-AMP3, these authors named the new bacteriocin as bactofensin. The similarity also inspired the authors to test possible antimicrobial activities listed for Ib-AMP3. In addition, the authors can also check whether the new peptide has a similar 3D structure. Thus, the output from the APD prediction programs can guide users to design new experiments to test the structure and activity of the newly identifi ed peptide based on the knowledge annotated for the most similar candidates in the database. Such a prediction of sequence, structure, and activity at multiple levels requires careful annotation of AMP information in the APD.
Peptide Design
The APD [ 10 , 11 ] also provides a useful platform for identifi cation of useful antimicrobials to combat diffi cult-to-kill pathogens such as human immune-defi ciency virus (HIV) and methicillinresistant Staphylococcus aureus (MRSA) [ 46 ] . Both database screening and database-guided design have been conducted. By screening a representative set of AMPs selected from the APD, we found several potent anti-HIV or anti-MRSA peptides [ 48 , 49 ] . New peptides were also obtained by modifying, shuffl ing, or hybriding natural sequences. Mathematically, a known peptide sequence can be shuffl ed into multiple sequences. Experimentally, we found that sequence shuffl ing could lead to all the possibilities: less active, equally active, and more potent sequences [ 49 ] . An MIT group developed a large-scale hybrid approach by combining sequence segments of ten residues (i.e., grammars). This grammar approach can generate new sequences, which may, or may not, be bactericidal [ 50 ] . A complete different approach in the form of combinatorial libraries can also be pursued [ 51 ] . In principle, the amino acid at each position of the peptide sequence can be changed into other amino acids. In practice, it is necessary to bias the choice of amino acids in order to obtain active peptides [ 52 ] . This is because the amino acid use in natural AMPs is biased. The APD enabled us to identify the frequently occurring amino acids for AMPs from a variety of life domains [ 10 , 53 ] . For example, the frequently occurring residues (≥8.5 %) are leucines, glycines, and lysines based on the average percentages of all the 2,329 peptides in the current APD. We demonstrated previously that these three amino acids contained suffi cient information for designing antibacterial peptides [ 11 ] .
Another important approach is de novo design (reviewed in ref. 6 ). We have recently developed a novel database approach [ 54 ] . A fl owchart for this approach is provided as Fig. 4 . This fl owchart contains two major tiers of information fi lters. The fi rst tier consists of an activity fi lter that enables one to obtain a set of peptides with desired activity. Table 3 lists 17 types of peptide activities, each of which contains a set of model peptides. In our design, Fig. 4 Ab initio peptide design based on the database fi ltering technology (DFT). The DFT tech developed recently [ 54 ] is composed of two layers of fi lters. The fi rst layer fi lter enables the identifi cation of a set of antimicrobial peptides with the desired activity from the antimicrobial peptide database ( see Table 7 ). This set of peptides is then used as templates to extract useful parameters for peptide design by utilizing the second layer fi lters (F1, F2, F3, …, Fn). These peptide parameters (P1, P2, P3, …, Pn) are combined to generate a single or limited number of peptides we selected a group of peptides with activity against gram-positive bacteria. This set of peptides formed the templates for extracting useful parameters for designing anti-MRSA peptides. The second tier contains numerous fi lters (F1, F2, …, Fn), each defi nes one parameter for the peptide (P1, P2, …, Pn). In determining these parameters, we followed the most probable principle, which projected the maximum for each parameter. Because the most probable parameters were used, the peptides assembled in this manner had a good chance to be antimicrobial. This is indeed the case. The designed peptide DFTamP1 rapidly killed MRSA USA300, a community-associated staphylococcal pathogen. It also showed some bacterial selectivity since DFTamP1 did not kill gramnegative bacteria E. coli , P. aeruginosa , or gram-positive B. subtilis . This success opens a new avenue to designing peptides with various types of activities (Table 7 ) . Because this new method differs from all existing de novo approaches, it was referred to as ab initio design [ 54 ] .
Concluding Remarks and Future Studies
The antimicrobial peptide database was constructed 10 years ago. It is an original construction in terms of both database design and peptide entries. Each peptide entry in the APD was manually collected from the literature using the public search engines such as PubMed, PDB, and Swiss-Prot. By following a set of rules for data registration, the APD presents a well-defi ned set of natural AMPs. To achieve a more complete sampling of natural AMPs, the database is extensively annotated and regularly updated. In addition, the pipeline design led to a powerful search engine. This unique database, therefore, constitutes the basis for developing new methods for peptide classifi cation, prediction and design. The APD is the fi rst to adopt both fi ve-kingdom and three-domain classifi cations, allowing users to search the AMP information from any kingdom (bacteria, protists, fungi, plants, and animals) or classes (e.g., insects, spiders, molluscs, crustaceans, reptiles, amphibians, fi sh, and birds) ( Table 4 ) . Once a domain is defi ned in the NAME fi eld, the APD behaves like a specialized database (e.g., plant AMPs, bacteriocins, and amphibian peptides). The APD also executed a new structure classifi cation scheme based on the types of secondary structures (α, β, αβ, and non-αβ) in a variety of 3D structures of AMPs (Fig. 1 ) [ 6 ] . Needless to say, the structures in each family can be further grouped based on the number of secondary structures (e.g., α-helix and β-strand). Due to a limited number of known 3D structures, we have proposed a universal classifi cation scheme here based on peptide chain bonding patterns (Fig. 2 ) . Since the information on peptide source, activity, and 3D structure is not required, this systematic classifi cation (Tables 9 , 10 , 11 , 12 , and 13 ) complements to the existing classifi cation methods for AMPs in a defi ned life kingdom such as bacteria and plants [ 39 -43 ] . It also offers an approach to unifying the classifi cation of antimicrobial peptides. This classifi cation is general and can be applied to other biologically active peptides.
There are various prediction methods for AMPs (reviewed in ref. 6 ). The APD is unique in that the prediction is highly coupled with the database. The upgraded version of the APD makes predictions in three steps by following the similarity principle. Each step deals with a specifi c question. The fi rst tier asks whether the peptide parameters of the input sequence fall within the database parameter space. Based on the amino acid composition analysis, the second tier asks which peptide class the input sequence belongs to. The third tier determines fi ve most similar sequences based on sequence alignment with all the peptides in the database. It is clear why we have been strict in following a set of rules in registering AMPs. Our practice allows us to more accurately map the parameter space for natural AMPs. When a large number of predicted or artifi cial sequences are included, such parameters could deviate from nature's parameters, thereby infl uencing the prediction quality. In addition, users can get an idea of the structural type and functional space of the input sequence by viewing the similar sequences already in the APD. For example, the input sequence is most likely to form a helix-bundle structure stabilized by three disulfi de bonds if the best match is a saposin-like protein. If the sequence matches human cathelicidin LL-37, it is likely to have multiple functions, ranging from antimicrobial, wound healing, to immune modulation. Like LL-37, the peptide may also have a broad-spectrum activity to kill bacteria, fungi, viruses, and parasites. This information will guide the users to validate both structure and activity of a new peptide.
Finally and importantly, the construction of this well-annotated database also enabled us to develop novel approaches for designing peptides with desired properties. Based on the database, we have tested two general approaches: peptide screening [ 48 , 49 ] and database-guided design [ 46 , 54 ] . In particular, we demonstrated the fi rst ab initio design based on the database by developing the database fi ltering technology [ 54 ] . This approach is not limited to the development of anti-MRSA peptides and can be applied to the design of peptides with other types of activities (Table 7 ) as well. It is also desirable that the designed peptides only kill a specifi c species. Our detailed annotations of AMP targeting organisms into the database set the stage for this effort. In addition, other database fi lters such as peptide selectivity and stability to proteases can be created as well. Taken together, the APD is a powerful engine for research and education in the fi eld of innate immunity and drug discovery.
